SPP1 may be considered as a general marker of cancer progression, would be valuable in combination with other biomarkers to guide patient stratification and treatment strategies, and would be an attractive therapeutic target due to its multiple roles in promoting tumor aggressiveness. This evidence concerns the gene SPP1 and neoplasm.